Guillaume Bardy1, Florence Fischer2, Anny Appert2, Bernadette Baldin3, Marie Stève3, Anne Spreux3, Thibaud Lavrut4, Milou-Daniel Drici5. 1. Regional Center of Pharmacovigilance « Nice-Alpes-Côte d'Azur », Cimiez Hospital, Nice, France; University of Nice Medical Center, Dept of Pharmacology, Pasteur Hospital, Nice, France. 2. University of Nice Medical Center, Dept of Haematology, Pasteur Hospital, Nice, France. 3. Regional Center of Pharmacovigilance « Nice-Alpes-Côte d'Azur », Cimiez Hospital, Nice, France. 4. University of Nice Medical Center, Dept of Pharmacology, Pasteur Hospital, Nice, France. 5. Regional Center of Pharmacovigilance « Nice-Alpes-Côte d'Azur », Cimiez Hospital, Nice, France; University of Nice Medical Center, Dept of Pharmacology, Pasteur Hospital, Nice, France. Electronic address: drici.md@chu-nice.fr.
Abstract
INTRODUCTION: No routine monitoring is required with factor Xa inhibitor rivaroxaban. Yet, its titration must be adapted, and its misuse may lead to increased risk of bleeding; therefore, therapeutic rivaroxaban monitoring might help in specific situations. MATERIAL AND METHODS: As asked by clinicians of our medical center, we measured rivaroxaban plasma concentrations in real conditions of use and checked their corresponding prescriptions. Measurement of 112 samples from 94 consecutive patients was performed with aBiophen LRT® anti-Xa chromogenic assay and compared blindly to the HPLC-MSMS "gold standard" method. Rivaroxaban was effectively given to 80 out of 94 patients but a mere 57% through an adequate prescription (within the scope of indications/titration). All chromogenic measurements were over the pre-specified 30ng/ml LOQ, whereas only 98 /114 samples had quantifiable rivaroxaban with HPLC-MSMS (LOQ 1ng/ml). Correlation between the two methods and linear regression were highly significant (p<0.0001). However, chromogenic values (mean 141.6ng/ml[96.6]) overestimated HPLC-MSMS values (119.7ng/ml[79.5]) by 22ng/ml according to Bland-Altman analysis (p<0.001). After re-assessing the chromogenic LOQ at 52ng/ml, 83 quantifiable samples had a mean concentration of 176.9ng/ml as compared to 158.5ng/ml with HPLC-MSMS, with no false positive anymore. CONCLUSIONS: In our medical center, rivaroxaban concentrations could be assessed by a rapid chromogenic method. Its pre-specified LOQ proved too high after being checked "on site" against HPLC-MSMS. Prescriptions for rivaroxaban were not optimal. An overestimated LOQ may impair observance monitoring or predispose patients to either risky thrombolysis or otherwise adjournable surgery in clinical practice.
RCT Entities:
INTRODUCTION: No routine monitoring is required with factor Xa inhibitor rivaroxaban. Yet, its titration must be adapted, and its misuse may lead to increased risk of bleeding; therefore, therapeutic rivaroxaban monitoring might help in specific situations. MATERIAL AND METHODS: As asked by clinicians of our medical center, we measured rivaroxaban plasma concentrations in real conditions of use and checked their corresponding prescriptions. Measurement of 112 samples from 94 consecutive patients was performed with a Biophen LRT® anti-Xa chromogenic assay and compared blindly to the HPLC-MSMS "gold standard" method. Rivaroxaban was effectively given to 80 out of 94 patients but a mere 57% through an adequate prescription (within the scope of indications/titration). All chromogenic measurements were over the pre-specified 30ng/ml LOQ, whereas only 98 /114 samples had quantifiable rivaroxaban with HPLC-MSMS (LOQ 1ng/ml). Correlation between the two methods and linear regression were highly significant (p<0.0001). However, chromogenic values (mean 141.6ng/ml[96.6]) overestimated HPLC-MSMS values (119.7ng/ml[79.5]) by 22ng/ml according to Bland-Altman analysis (p<0.001). After re-assessing the chromogenic LOQ at 52ng/ml, 83 quantifiable samples had a mean concentration of 176.9ng/ml as compared to 158.5ng/ml with HPLC-MSMS, with no false positive anymore. CONCLUSIONS: In our medical center, rivaroxaban concentrations could be assessed by a rapid chromogenic method. Its pre-specified LOQ proved too high after being checked "on site" against HPLC-MSMS. Prescriptions for rivaroxaban were not optimal. An overestimated LOQ may impair observance monitoring or predispose patients to either risky thrombolysis or otherwise adjournable surgery in clinical practice.
Authors: Fadiea Al-Aieshy; Rickard E Malmström; Jovan Antovic; Anton Pohanka; Yuko Rönquist-Nii; Maria Berndtsson; Faris Al-Khalili; Mika Skeppholm Journal: Eur J Clin Pharmacol Date: 2016-04-11 Impact factor: 2.953
Authors: Priscilla Bento Matos Derogis; Livia Rentas Sanches; Valdir Fernandes de Aranda; Marjorie Paris Colombini; Cristóvão Luis Pitangueira Mangueira; Marcelo Katz; Adriana Caschera Leme Faulhaber; Claudio Ernesto Albers Mendes; Carlos Eduardo Dos Santos Ferreira; Carolina Nunes França; João Carlos de Campos Guerra Journal: PLoS One Date: 2017-02-07 Impact factor: 3.240
Authors: Tamana Meihandoest; Jan-Dirk Studt; Adriana Mendez; Lorenzo Alberio; Pierre Fontana; Walter A Wuillemin; Adrian Schmidt; Lukas Graf; Bernhard Gerber; Ursula Amstutz; Cedric Bovet; Thomas C Sauter; Lars M Asmis; Michael Nagler Journal: Front Cardiovasc Med Date: 2022-03-17